Screener
Bioventus BVS SG&A
SG&A at other companies
Other financials
Where this comes from
Reported directly by Bioventus in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Bioventus’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:43 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001665988-26-000042
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 | Six Months Ended / June 27, 2026 | Six Months Ended / June 28, 2025 |
|---|---|---|---|---|
| Net sales | $153,208 | $147,660 | $285,297 | $271,536 |
| Cost of sales (including depreciation and amortization of $9,893, $10,603, $19,980 and $20,868, respectively) | 47,542 | 45,570 | 88,862 | 86,390 |
| Gross profit | 105,666 | 102,090 | 196,435 | 185,146 |
| Selling, general and administrative expense | 82,740 | 79,110 | 161,065 | 152,612 |
| Research and development expense | 3,173 | 3,172 | 5,640 | 6,183 |
| Restructuring costs | (415) | — | 39 | — |
| Depreciation and amortization | 1,041 | 1,439 | 2,148 | 3,032 |
| Loss on disposals | — | 1 | — | 82 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bioventus's SG&A?
- Bioventus (BVS) reported SG&A of $82.74M in Q2 2026.
- How has Bioventus's SG&A changed year-over-year?
- Bioventus's SG&A increased by 4.6% year-over-year, from $79.11M to $82.74M.
- What is the long-term trend for Bioventus's SG&A?
- Over 4 years (2021 to 2025), Bioventus's SG&A has grown at a 5.4% compound annual growth rate (CAGR), from $254.25M to $314.03M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Bioventus's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude